Evolocumab In Patients Without Significant At...

Cardiovascular protection during cancer treatment is critical to help prevent complications such as heart failure. Patients should be educated on risk factors, symptom awareness, and heart-healthy behaviors. Oncologists should incorporate cardiovascular risk assessment and survei ...  Show more

Nonobstructive hypertrophic cardiomyopathy (HCM) represents one of the greatest areas of unmet need in HCM management. A key question is identifying the primary driver of symptoms in these patients, as many experience significant functional limitations despite the absence of left ...  Show more

In patients with heart failure with low ejection fraction and chronic coronary disease without unstable symptoms, does stenting open blocked coronary arteries extend life or reduce hospitalizations? There is some literature to suggest those with low EF may benefit from revascular ...  Show more

In this episode, Dr. Harlan Krumholz introduces the September 16, 2025 issue of JACC, which features studies that challenge conventional clinical thinking, including a detailed ECMO physiology study showing that higher ECMO flow does not uniformly raise pulmonary capillary wedge ...  Show more

In this episode, Editor-in-Chief Harlan Krumholz explores the evolving landscape of cardiovascular medicine, beginning with a call for responsible stewardship of artificial intelligence. Highlights include a major registry study on percutaneous aspiration for right-sided endocard ...  Show more

 In this week’s View, Dr. Eagle discusses the value of the balloon pulmonary angioplasty procedure for patients with chronic thromboembolic pulmonary hypertension. He then reviews the sub analysis of the HOST EXAM trial assessing the benefit of aspirin versus clopidogrel as a mai ...  Show more